| Literature DB >> 30127770 |
Mohamed Zommiti1, Mélyssa Cambronel2, Olivier Maillot2, Magalie Barreau2, Khaled Sebei1, Marc Feuilloley2, Mounir Ferchichi1,3, Nathalie Connil2.
Abstract
Enterococcus faecium strains were isolated from an original biotope, artisanal dried Tunisian meat "Dried Ossban," and evaluated for safety and capacity as probiotics. Gram-positive, catalase negative, and bacteriocin-producing bacteria were screened using selective microbiological media. All isolates were identified by phenotypic and molecular tools. Five E. faecium strains (MZF1, MZF2, MZF3, MZF4, and MZF5) were selected and further assessed for their probiotic properties. They were found to be resistant to the physiological concentrations of bile salts, and the harsh conditions of the gastrointestinal tract, and showed autoaggregation and adhesion ability. All these isolates possess at least one enterocin and could efficiently inhibit the growth of Listeria innocua HPB13. The analysis of their safety profile revealed for almost all the strains the absence of cytotoxicity and virulence determinants, and susceptibility to clinically important antibiotics such as vancomycin. These data suggest that these bacteria, isolated from "Dried Ossban," do not present a risk to human health, and may be considered as interesting candidates for future use as probiotics and bioprotective cultures for application in the food and/or feed industries.Entities:
Keywords: Dried Ossban; Enterococcus faecium; antibiotic resistance; probiotics; safety; virulence determinants
Year: 2018 PMID: 30127770 PMCID: PMC6088202 DOI: 10.3389/fmicb.2018.01685
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
PCR primers used for detection of virulence determinants, antibiotic resistance, biogenic amines, and enterocin genes.
| Target genes | Oligonucleotide sequence (5′–3′) | Product size (bp) | Reference |
|---|---|---|---|
| F: AAGAAAAAGAAGTAGACCAAC | 1553 | ||
| R: AAACGGCAAGACAAGTAAATA | |||
| F: ACCCCGTATCATTGGTTT | 419 | ||
| R: ACGCATTGCTTTTCCATC | |||
| F: TTGCTAATGCTAGTCCACGACC | 933 | ||
| R: GCGTCAACACTTGCATTGCCGAA | |||
| F: AAAGTAGAATTAGATCACAC | 350 | ||
| R: TCTATCACATTCGGTTGCG | |||
| F: CCCCTTTAACGCTAATACGATCAA | 1030 | ||
| R: CATGAATAGAATAAAAGTTGCAAT | |||
| F: GTGACAAACCGGAGGCGAGGA | 433 | ||
| R: CCGCCATCCTCCTGCAAAAAA | |||
| F: AGATGGTATTGTTTCTTATG | 367 | ||
| R: AGACCATACACCATAACCTT | |||
| F: AAYTCNTTYGAYTTYGARAARGARG | 534 | ||
| R: ATNGGNGANCCDATCATYTTRTGNCC | |||
| F: ACATAGTCAACCATRTTGAA | 1100 | ||
| R: CAAATGGAAGAAGAAGTAGG | |||
| F: AAATATTATGGAAATGGAGTGTAT | 126 | ||
| R: GCACTTCCCTGGAATTGCTC | |||
| F: GAAAATGATCACAGAATGCCTA | |||
| R: GTTGCATTTAGAGTATACATTTG | 162 | ||
| F: TATGGTAATGGTGTTTATTGTAAT | |||
| R: ATGTCCCATACCTGCCAAAC | 112 | ||
List of antibiotics used in the study.
| Name of drug | Antibiotic group | Mode of action |
|---|---|---|
| Ampicillin | β-Lactams | Inhibitors of the cell wall synthesis |
| Vancomycin | Glycopeptides | |
| Ofloxacin | Quinolones | Inhibiting DNA replication and transcription |
| Gentamycin | Aminoglycosides | Inhibitors of protein synthesis |
| Erythromycin | Macrolides | |
| Chloramphenicol | Others | |
| Tetracycline | Tetracyclines | |
Low pH and acidic conditions tolerance.
| Isolates | Mean of viable count (log10 CFU/ml) | |||
|---|---|---|---|---|
| Time of exposure (h) | ||||
| 0 | 1 | 2 | 3 | |
| MZF1 | 6.71 | 6.46 | 6.50 | 6.47 |
| MZF2 | 6.61 | 6.59 | 6.52 | 6.49 |
| MZF3 | 7.02 | 6.89 | 6.61 | 6.57 |
| MZF4 | 6.69 | 6.51 | 6.43 | 6.39 |
| MZF5 | 7.09 | 6.92 | 6.79 | 6.67 |
Bile salts tolerance.
| Isolates | Mean of viable count (log10 CFU/ml) | |||
|---|---|---|---|---|
| Time of exposure (h) | ||||
| 0 | 1 | 2 | 3 | |
| MZF1 | 6.67 | 6.59 | 6.54 | 6.51 |
| MZF2 | 6.57 | 6.54 | 6.49 | 6.44 |
| MZF3 | 7.01 | 6.74 | 6.62 | 6.50 |
| MZF4 | 6.62 | 6.57 | 6.51 | 6.42 |
| MZF5 | 7.04 | 6.76 | 6.59 | 6.54 |
PCR results of virulence and antibiotic resistance genes.
| Genotype profile | |
|---|---|
| MZF1 | agg+ gelE+ esp- ace- vanA- vanB- |
| MZF2 | agg- gelE- esp- ace- vanA- vanB- |
| MZF3 | agg- gelE- esp- ace- vanA- vanB- |
| MZF4 | agg- gelE+ esp- ace- vanA- vanB- |
| MZF5 | agg- gelE- esp- ace- vanA- vanB- |
Antibiotic susceptibility.
| Antibiotic | MIC breakpoint recommendation of CLSI for | Strain/antibiotic susceptibility | ||||||
|---|---|---|---|---|---|---|---|---|
| S | I | R | MZF1 | MZF2 | MZF3 | MZF4 | MZF5 | |
| Ampicillin | ≤8 | – | ≥16 | <1 (S) | 0.25 (S) | <0.125 (S) | <0.125 (S) | <0.125 (S) |
| Vancomycin | ≤4 | 8–16 | ≥32 | 2 (S) | 2 (S) | 2 (S) | 2 (S) | 2 (S) |
| Ofloxacin | ≤1 | 2 | ≥4 | 32(R) | 32 (R) | 16 (R) | 32 (R) | 32 (R) |
| Gentamicin | ≤500 | N/A | ≥500 | 128 (S) | 128 (S) | 256 (S) | 256 (S) | 256 (S) |
| Erythromycin | ≤0.5 | 1–4 | ≥8 | 8 (R) | 8 (R) | 4 (I) | 16 (R) | 16 (R) |
| Chloramphenicol | ≤8 | 16 | ≥32 | 2 (S) | 8 (S) | 4 (S) | 4 (S) | 4 (S) |
| Tetracyclin | ≤4 | 8 | ≥16 | <1(S) | <1(S) | <1 (S) | <1(S) | <1 (S) |
Analysis for enterocins A, B, and P genes and antibacterial activity.
| MZF1 | MZF2 | MZF3 | MZF4 | MZF5 | |
|---|---|---|---|---|---|
| Enterocin A ( | + | + | - | + | + |
| Enterocin B ( | + | + | + | + | + |
| Enterocin P ( | + | + | - | + | + |
| +++ | +++ | + | +++ | +++ | |
| +++ | + | - | ++ | +++ | |
| - | - | - | - | - | |
| - | - | - | - | - | |
| - | - | - | - | - | |
| - | - | - | - | - | |